Skip to main content

Some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. We apologize for the inconvenience and appreciate your patience. For assistance, please contact our Help Desk at info@ncbi.nlm.nih.gov.

Thorax logoLink to Thorax
. 1998 Jun;53(6):501–505. doi: 10.1136/thx.53.6.501

Alpha1-antitrypsin deficiency, cirrhosis and emphysema

R Mahadeva 1, D Lomas 1
PMCID: PMC1745245  PMID: 9713452

Full Text

The Full Text of this article is available as a PDF (206.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beatty K., Bieth J., Travis J. Kinetics of association of serine proteinases with native and oxidized alpha-1-proteinase inhibitor and alpha-1-antichymotrypsin. J Biol Chem. 1980 May 10;255(9):3931–3934. [PubMed] [Google Scholar]
  2. Brantly M., Nukiwa T., Crystal R. G. Molecular basis of alpha-1-antitrypsin deficiency. Am J Med. 1988 Jun 24;84(6A):13–31. doi: 10.1016/0002-9343(88)90154-4. [DOI] [PubMed] [Google Scholar]
  3. Bruce D., Perry D. J., Borg J. Y., Carrell R. W., Wardell M. R. Thromboembolic disease due to thermolabile conformational changes of antithrombin Rouen-VI (187 Asn-->Asp) J Clin Invest. 1994 Dec;94(6):2265–2274. doi: 10.1172/JCI117589. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Carp H., Miller F., Hoidal J. R., Janoff A. Potential mechanism of emphysema: alpha 1-proteinase inhibitor recovered from lungs of cigarette smokers contains oxidized methionine and has decreased elastase inhibitory capacity. Proc Natl Acad Sci U S A. 1982 Mar;79(6):2041–2045. doi: 10.1073/pnas.79.6.2041. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Carrell R. W., Jeppsson J. O., Laurell C. B., Brennan S. O., Owen M. C., Vaughan L., Boswell D. R. Structure and variation of human alpha 1-antitrypsin. Nature. 1982 Jul 22;298(5872):329–334. doi: 10.1038/298329a0. [DOI] [PubMed] [Google Scholar]
  6. Carrell R. W., Lomas D. A. Conformational disease. Lancet. 1997 Jul 12;350(9071):134–138. doi: 10.1016/S0140-6736(97)02073-4. [DOI] [PubMed] [Google Scholar]
  7. Carrell R. W., Stein P. E., Fermi G., Wardell M. R. Biological implications of a 3 A structure of dimeric antithrombin. Structure. 1994 Apr 15;2(4):257–270. doi: 10.1016/s0969-2126(00)00028-9. [DOI] [PubMed] [Google Scholar]
  8. Courtney M., Jallat S., Tessier L. H., Benavente A., Crystal R. G., Lecocq J. P. Synthesis in E. coli of alpha 1-antitrypsin variants of therapeutic potential for emphysema and thrombosis. Nature. 1985 Jan 10;313(5998):149–151. doi: 10.1038/313149a0. [DOI] [PubMed] [Google Scholar]
  9. Eldering E., Verpy E., Roem D., Meo T., Tosi M. COOH-terminal substitutions in the serpin C1 inhibitor that cause loop overinsertion and subsequent multimerization. J Biol Chem. 1995 Feb 10;270(6):2579–2587. doi: 10.1074/jbc.270.6.2579. [DOI] [PubMed] [Google Scholar]
  10. Elliott P. R., Abrahams J. P., Lomas D. A. Wild-type alpha 1-antitrypsin is in the canonical inhibitory conformation. J Mol Biol. 1998 Jan 23;275(3):419–425. doi: 10.1006/jmbi.1997.1458. [DOI] [PubMed] [Google Scholar]
  11. Elliott P. R., Lomas D. A., Carrell R. W., Abrahams J. P. Inhibitory conformation of the reactive loop of alpha 1-antitrypsin. Nat Struct Biol. 1996 Aug;3(8):676–681. doi: 10.1038/nsb0896-676. [DOI] [PubMed] [Google Scholar]
  12. Elliott P. R., Stein P. E., Bilton D., Carrell R. W., Lomas D. A. Structural explanation for the deficiency of S alpha 1-antitrypsin. Nat Struct Biol. 1996 Nov;3(11):910–911. doi: 10.1038/nsb1196-910. [DOI] [PubMed] [Google Scholar]
  13. Eriksson S., Carlson J., Velez R. Risk of cirrhosis and primary liver cancer in alpha 1-antitrypsin deficiency. N Engl J Med. 1986 Mar 20;314(12):736–739. doi: 10.1056/NEJM198603203141202. [DOI] [PubMed] [Google Scholar]
  14. Faber J. P., Poller W., Olek K., Baumann U., Carlson J., Lindmark B., Eriksson S. The molecular basis of alpha 1-antichymotrypsin deficiency in a heterozygote with liver and lung disease. J Hepatol. 1993 Jul;18(3):313–321. doi: 10.1016/s0168-8278(05)80275-2. [DOI] [PubMed] [Google Scholar]
  15. Griffith M. E., Lovegrove J. U., Gaskin G., Whitehouse D. B., Pusey C. D. C-antineutrophil cytoplasmic antibody positivity in vasculitis patients is associated with the Z allele of alpha-1-antitrypsin, and P-antineutrophil cytoplasmic antibody positivity with the S allele. Nephrol Dial Transplant. 1996 Mar;11(3):438–443. [PubMed] [Google Scholar]
  16. Huber R., Carrell R. W. Implications of the three-dimensional structure of alpha 1-antitrypsin for structure and function of serpins. Biochemistry. 1989 Nov 14;28(23):8951–8966. doi: 10.1021/bi00449a001. [DOI] [PubMed] [Google Scholar]
  17. Jaffe H. A., Danel C., Longenecker G., Metzger M., Setoguchi Y., Rosenfeld M. A., Gant T. W., Thorgeirsson S. S., Stratford-Perricaudet L. D., Perricaudet M. Adenovirus-mediated in vivo gene transfer and expression in normal rat liver. Nat Genet. 1992 Aug;1(5):372–378. doi: 10.1038/ng0892-372. [DOI] [PubMed] [Google Scholar]
  18. Janus E. D., Phillips N. T., Carrell R. W. Smoking, lung function, and alpha 1-antitrypsin deficiency. Lancet. 1985 Jan 19;1(8421):152–154. doi: 10.1016/s0140-6736(85)91916-6. [DOI] [PubMed] [Google Scholar]
  19. Jeppsson J. O. Amino acid substitution Glu leads to Lys alpha1-antitrypsin PiZ. FEBS Lett. 1976 Jun 1;65(2):195–197. doi: 10.1016/0014-5793(76)80478-4. [DOI] [PubMed] [Google Scholar]
  20. Kay M. A., Baley P., Rothenberg S., Leland F., Fleming L., Ponder K. P., Liu T., Finegold M., Darlington G., Pokorny W. Expression of human alpha 1-antitrypsin in dogs after autologous transplantation of retroviral transduced hepatocytes. Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):89–93. doi: 10.1073/pnas.89.1.89. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Kim J., Lee K. N., Yi G. S., Yu M. H. A thermostable mutation located at the hydrophobic core of alpha 1-antitrypsin suppresses the folding defect of the Z-type variant. J Biol Chem. 1995 Apr 14;270(15):8597–8601. doi: 10.1074/jbc.270.15.8597. [DOI] [PubMed] [Google Scholar]
  22. King M. A., Stone J. A., Diaz P. T., Mueller C. F., Becker W. J., Gadek J. E. Alpha 1-antitrypsin deficiency: evaluation of bronchiectasis with CT. Radiology. 1996 Apr;199(1):137–141. doi: 10.1148/radiology.199.1.8633137. [DOI] [PubMed] [Google Scholar]
  23. Kwon K. S., Kim J., Shin H. S., Yu M. H. Single amino acid substitutions of alpha 1-antitrypsin that confer enhancement in thermal stability. J Biol Chem. 1994 Apr 1;269(13):9627–9631. [PubMed] [Google Scholar]
  24. Larsson C. Natural history and life expectancy in severe alpha1-antitrypsin deficiency, Pi Z. Acta Med Scand. 1978;204(5):345–351. doi: 10.1111/j.0954-6820.1978.tb08452.x. [DOI] [PubMed] [Google Scholar]
  25. Le A., Ferrell G. A., Dishon D. S., Le Q. Q., Sifers R. N. Soluble aggregates of the human PiZ alpha 1-antitrypsin variant are degraded within the endoplasmic reticulum by a mechanism sensitive to inhibitors of protein synthesis. J Biol Chem. 1992 Jan 15;267(2):1072–1080. [PubMed] [Google Scholar]
  26. Lindo V. S., Kakkar V. V., Learmonth M., Melissari E., Zappacosta F., Panico M., Morris H. R. Antithrombin-TRI (Ala382 to Thr) causing severe thromboembolic tendency undergoes the S-to-R transition and is associated with a plasma-inactive high-molecular-weight complex of aggregated antithrombin. Br J Haematol. 1995 Mar;89(3):589–601. doi: 10.1111/j.1365-2141.1995.tb08368.x. [DOI] [PubMed] [Google Scholar]
  27. Llewellyn-Jones C. G., Lomas D. A., Carrell R. W., Stockley R. A. The effect of the Z mutation on the ability of alpha 1-antitrypsin to prevent neutrophil mediated tissue damage. Biochim Biophys Acta. 1994 Nov 29;1227(3):155–160. doi: 10.1016/0925-4439(94)90089-2. [DOI] [PubMed] [Google Scholar]
  28. Lomas D. A., Elliott P. R., Chang W. S., Wardell M. R., Carrell R. W. Preparation and characterization of latent alpha 1-antitrypsin. J Biol Chem. 1995 Mar 10;270(10):5282–5288. doi: 10.1074/jbc.270.10.5282. [DOI] [PubMed] [Google Scholar]
  29. Lomas D. A., Elliott P. R., Sidhar S. K., Foreman R. C., Finch J. T., Cox D. W., Whisstock J. C., Carrell R. W. alpha 1-Antitrypsin Mmalton (Phe52-deleted) forms loop-sheet polymers in vivo. Evidence for the C sheet mechanism of polymerization. J Biol Chem. 1995 Jul 14;270(28):16864–16870. doi: 10.1074/jbc.270.28.16864. [DOI] [PubMed] [Google Scholar]
  30. Lomas D. A., Evans D. L., Finch J. T., Carrell R. W. The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature. 1992 Jun 18;357(6379):605–607. doi: 10.1038/357605a0. [DOI] [PubMed] [Google Scholar]
  31. Lomas D. A., Evans D. L., Stone S. R., Chang W. S., Carrell R. W. Effect of the Z mutation on the physical and inhibitory properties of alpha 1-antitrypsin. Biochemistry. 1993 Jan 19;32(2):500–508. doi: 10.1021/bi00053a014. [DOI] [PubMed] [Google Scholar]
  32. Lomas D. A., Finch J. T., Seyama K., Nukiwa T., Carrell R. W. Alpha 1-antitrypsin Siiyama (Ser53-->Phe). Further evidence for intracellular loop-sheet polymerization. J Biol Chem. 1993 Jul 25;268(21):15333–15335. [PubMed] [Google Scholar]
  33. Massaro G. D., Massaro D. Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats. Nat Med. 1997 Jun;3(6):675–677. doi: 10.1038/nm0697-675. [DOI] [PubMed] [Google Scholar]
  34. Mast A. E., Enghild J. J., Pizzo S. V., Salvesen G. Analysis of the plasma elimination kinetics and conformational stabilities of native, proteinase-complexed, and reactive site cleaved serpins: comparison of alpha 1-proteinase inhibitor, alpha 1-antichymotrypsin, antithrombin III, alpha 2-antiplasmin, angiotensinogen, and ovalbumin. Biochemistry. 1991 Feb 12;30(6):1723–1730. doi: 10.1021/bi00220a039. [DOI] [PubMed] [Google Scholar]
  35. Mast A. E., Enghild J. J., Salvesen G. Conformation of the reactive site loop of alpha 1-proteinase inhibitor probed by limited proteolysis. Biochemistry. 1992 Mar 17;31(10):2720–2728. doi: 10.1021/bi00125a012. [DOI] [PubMed] [Google Scholar]
  36. Morrison H. M., Kramps J. A., Burnett D., Stockley R. A. Lung lavage fluid from patients with alpha 1-proteinase inhibitor deficiency or chronic obstructive bronchitis: anti-elastase function and cell profile. Clin Sci (Lond) 1987 Mar;72(3):373–381. doi: 10.1042/cs0720373. [DOI] [PubMed] [Google Scholar]
  37. Ogushi F., Fells G. A., Hubbard R. C., Straus S. D., Crystal R. G. Z-type alpha 1-antitrypsin is less competent than M1-type alpha 1-antitrypsin as an inhibitor of neutrophil elastase. J Clin Invest. 1987 Nov;80(5):1366–1374. doi: 10.1172/JCI113214. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Patston P. A., Hauert J., Michaud M., Schapira M. Formation and properties of C1-inhibitor polymers. FEBS Lett. 1995 Jul 24;368(3):401–404. doi: 10.1016/0014-5793(95)00694-5. [DOI] [PubMed] [Google Scholar]
  39. Poller W., Faber J. P., Weidinger S., Tief K., Scholz S., Fischer M., Olek K., Kirchgesser M., Heidtmann H. H. A leucine-to-proline substitution causes a defective alpha 1-antichymotrypsin allele associated with familial obstructive lung disease. Genomics. 1993 Sep;17(3):740–743. doi: 10.1006/geno.1993.1396. [DOI] [PubMed] [Google Scholar]
  40. Potempa J., Korzus E., Travis J. The serpin superfamily of proteinase inhibitors: structure, function, and regulation. J Biol Chem. 1994 Jun 10;269(23):15957–15960. [PubMed] [Google Scholar]
  41. Roberts E. A., Cox D. W., Medline A., Wanless I. R. Occurrence of alpha-1-antitrypsin deficiency in 155 patients with alcoholic liver disease. Am J Clin Pathol. 1984 Oct;82(4):424–427. doi: 10.1093/ajcp/82.4.424. [DOI] [PubMed] [Google Scholar]
  42. Rosenfeld M. A., Siegfried W., Yoshimura K., Yoneyama K., Fukayama M., Stier L. E., Päkkö P. K., Gilardi P., Stratford-Perricaudet L. D., Perricaudet M. Adenovirus-mediated transfer of a recombinant alpha 1-antitrypsin gene to the lung epithelium in vivo. Science. 1991 Apr 19;252(5004):431–434. doi: 10.1126/science.2017680. [DOI] [PubMed] [Google Scholar]
  43. Ryu S. E., Choi H. J., Kwon K. S., Lee K. N., Yu M. H. The native strains in the hydrophobic core and flexible reactive loop of a serine protease inhibitor: crystal structure of an uncleaved alpha1-antitrypsin at 2.7 A. Structure. 1996 Oct 15;4(10):1181–1192. doi: 10.1016/s0969-2126(96)00126-8. [DOI] [PubMed] [Google Scholar]
  44. Schreuder H. A., de Boer B., Dijkema R., Mulders J., Theunissen H. J., Grootenhuis P. D., Hol W. G. The intact and cleaved human antithrombin III complex as a model for serpin-proteinase interactions. Nat Struct Biol. 1994 Jan;1(1):48–54. doi: 10.1038/nsb0194-48. [DOI] [PubMed] [Google Scholar]
  45. Schulze A. J., Baumann U., Knof S., Jaeger E., Huber R., Laurell C. B. Structural transition of alpha 1-antitrypsin by a peptide sequentially similar to beta-strand s4A. Eur J Biochem. 1990 Nov 26;194(1):51–56. doi: 10.1111/j.1432-1033.1990.tb19425.x. [DOI] [PubMed] [Google Scholar]
  46. Seyama K., Nukiwa T., Takabe K., Takahashi H., Miyake K., Kira S. Siiyama (serine 53 (TCC) to phenylalanine 53 (TTC)). A new alpha 1-antitrypsin-deficient variant with mutation on a predicted conserved residue of the serpin backbone. J Biol Chem. 1991 Jul 5;266(19):12627–12632. [PubMed] [Google Scholar]
  47. Sidhar S. K., Lomas D. A., Carrell R. W., Foreman R. C. Mutations which impede loop/sheet polymerization enhance the secretion of human alpha 1-antitrypsin deficiency variants. J Biol Chem. 1995 Apr 14;270(15):8393–8396. doi: 10.1074/jbc.270.15.8393. [DOI] [PubMed] [Google Scholar]
  48. Snider G. L. Emphysema: the first two centuries--and beyond. A historical overview, with suggestions for future research: Part 2. Am Rev Respir Dis. 1992 Dec;146(6):1615–1622. doi: 10.1164/ajrccm/146.6.1615. [DOI] [PubMed] [Google Scholar]
  49. Stein P. D., Leu J. D., Welch M. H., Guenter C. A. Pathophysiology of the pulmonary circulation in emphysema associated with alpha antitrypsin deficiency. Circulation. 1971 Feb;43(2):227–239. doi: 10.1161/01.cir.43.2.227. [DOI] [PubMed] [Google Scholar]
  50. Sveger T. Liver disease in alpha1-antitrypsin deficiency detected by screening of 200,000 infants. N Engl J Med. 1976 Jun 10;294(24):1316–1321. doi: 10.1056/NEJM197606102942404. [DOI] [PubMed] [Google Scholar]
  51. Sveger T. The natural history of liver disease in alpha 1-antitrypsin deficient children. Acta Paediatr Scand. 1988 Nov;77(6):847–851. doi: 10.1111/j.1651-2227.1988.tb10767.x. [DOI] [PubMed] [Google Scholar]
  52. Teckman J. H., Perlmutter D. H. The endoplasmic reticulum degradation pathway for mutant secretory proteins alpha1-antitrypsin Z and S is distinct from that for an unassembled membrane protein. J Biol Chem. 1996 May 31;271(22):13215–13220. doi: 10.1074/jbc.271.22.13215. [DOI] [PubMed] [Google Scholar]
  53. Wewers M. D., Casolaro M. A., Sellers S. E., Swayze S. C., McPhaul K. M., Wittes J. T., Crystal R. G. Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N Engl J Med. 1987 Apr 23;316(17):1055–1062. doi: 10.1056/NEJM198704233161704. [DOI] [PubMed] [Google Scholar]
  54. Wu Y., Whitman I., Molmenti E., Moore K., Hippenmeyer P., Perlmutter D. H. A lag in intracellular degradation of mutant alpha 1-antitrypsin correlates with the liver disease phenotype in homozygous PiZZ alpha 1-antitrypsin deficiency. Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):9014–9018. doi: 10.1073/pnas.91.19.9014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Yoshida A., Lieberman J., Gaidulis L., Ewing C. Molecular abnormality of human alpha1-antitrypsin variant (Pi-ZZ) associated with plasma activity deficiency. Proc Natl Acad Sci U S A. 1976 Apr;73(4):1324–1328. doi: 10.1073/pnas.73.4.1324. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Yu M. H., Lee K. N., Kim J. The Z type variation of human alpha 1-antitrypsin causes a protein folding defect. Nat Struct Biol. 1995 May;2(5):363–367. doi: 10.1038/nsb0595-363. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES